Press Release Archive
Press Releases
April 2019
04.26.2019 Medicines Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall of One Lot of ThermaCare® Back Pain Therapy HeatWraps, up to 16HR pain relief, Due To Out of Specification Results for High Cell Temperature 04.26.2019 Medicines Pfizer Receives Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer 04.25.2019 Finance Pfizer Hosts Annual Meeting of Shareholders 04.18.2019 Research Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis 04.18.2019 Finance Pfizer Invites Public to Listen to Webcast of April 25 Annual Meeting of Shareholders 04.13.2019 Research Vaccines Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older 04.04.2019 Medicines U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer 04.03.2019 Medicines VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer 04.02.2019 Research Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy
March 2019
03.20.2019 Finance Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics 03.19.2019 Research Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer 03.19.2019 Finance Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.